These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9498772)

  • 1. Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.
    Shafren DR; Dorahy DJ; Thorne RF; Kinoshita T; Barry RD; Burns GF
    J Immunol; 1998 Mar; 160(5):2318-23. PubMed ID: 9498772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
    Johansson ES; Xing L; Cheng RH; Shafren DR
    J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
    Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
    Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
    Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
    J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
    Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR
    J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two clusters of mutations map distinct receptor-binding sites of echovirus 11 for the decay-accelerating factor (CD55) and for canyon-binding receptors.
    Rezaikin AV; Novoselov AV; Sergeev AG; Fadeyev FA; Lebedev SV
    Virus Res; 2009 Oct; 145(1):74-9. PubMed ID: 19540285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.
    Shafren DR; Dorahy DJ; Ingham RA; Burns GF; Barry RD
    J Virol; 1997 Jun; 71(6):4736-43. PubMed ID: 9151867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
    Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
    Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
    Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
    J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor.
    Powell RM; Schmitt V; Ward T; Goodfellow I; Evans DJ; Almond JW
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1707-13. PubMed ID: 9680134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.
    Spiller OB; Goodfellow IG; Evans DJ; Almond JW; Morgan BP
    J Infect Dis; 2000 Jan; 181(1):340-3. PubMed ID: 10608785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells.
    Polacek C; Ekström JO; Lundgren A; Lindberg AM
    Virus Res; 2005 Nov; 113(2):107-15. PubMed ID: 15964091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells.
    Chevaliez S; Balanant J; Maillard P; Lone YC; Lemonnier FA; Delpeyroux F
    Virology; 2008 Nov; 381(2):203-14. PubMed ID: 18823925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent oncolytic activity of human enteroviruses against human prostate cancer.
    Berry LJ; Au GG; Barry RD; Shafren DR
    Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
    Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
    J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
    Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
    J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells.
    Agrez MV; Shafren DR; Gu X; Cox K; Sheppard D; Barry RD
    Virology; 1997 Dec; 239(1):71-7. PubMed ID: 9426447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF.
    Okura E; Ishimaru A; Yamamoto A; Nakatsu S; Shirakura R; Okabe M; Sawa Y; Fukuzawa M; Okumura M; Miyagawa S
    Xenotransplantation; 2008; 15(6):365-73. PubMed ID: 19152664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59.
    Goodfellow IG; Powell RM; Ward T; Spiller OB; Almond JW; Evans DJ
    J Gen Virol; 2000 May; 81(Pt 5):1393-401. PubMed ID: 10769083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.